Abstract
Systemic high-dose methotrexate (HD-MTX) is the most effective chemotherapeutic agent in the treatment of primary central nervous system lymphoma (PCNSL). Leptomeningeal involvement is common and intrathecal methotrexate (IT-MTX) is frequently used in combination with HD-MTX, but its benefits are not established. Using a case-controlled retrospective study, matching patients treated with HD-MTX with or without IT-MTX, we found no difference in survival, disease control, or neurotoxicity.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antimetabolites, Antineoplastic / administration & dosage*
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use
-
Case-Control Studies
-
Central Nervous System Neoplasms / drug therapy*
-
Dose-Response Relationship, Drug
-
Female
-
Humans
-
Injections, Spinal
-
Lymphoma / drug therapy*
-
Male
-
Methotrexate / administration & dosage*
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Middle Aged
-
Nervous System / drug effects
-
Retrospective Studies
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Methotrexate